Business Context and Reporting Period
Company: Akebia Therapeutics, Inc. (AKBA)
Filing Type: Form 8-K (Current Report)
Date of Report: February 14, 2020
Subject: Item 8.01 Other Events - Letter Agreement regarding a Priority Review Voucher (PRV).
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figure disclosed is a contingent payment obligation:
- Contingent Payment: $10 million payable to Vifor (International) Ltd.
- Payment Timing: Within fifteen business days after the closing of the PRV Purchase.
Material Changes and Events
Akebia entered into a Letter Agreement with Vifor Pharma concerning a Priority Review Voucher (PRV) associated with Akebia's investigational drug, vadadustat (an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for anemia due to chronic kidney disease). Key terms include:
- PRV Utility: Entitles the holder to priority FDA review, reducing target review time to six months.
- Assignment Conditions: Vifor must retain rights to the PRV until Akebia and Vifor either (a) enter a definitive agreement for Vifor to assign the PRV to Akebia for vadadustat's NDA, or (b) mutually decide to sell the PRV and share proceeds.
- Context: This follows an April 8, 2019, Amended and Restated License Agreement where Akebia granted Vifor an exclusive license to sell vadadustat in the U.S. to Fresenius Kidney Care Group and certain third-party dialysis organizations.
Outlook, Risks, and Management Commentary
Outlook: The agreement supports Akebia's planned New Drug Application (NDA) for vadadustat for the treatment of anemia due to CKD in both dialysis-dependent and non-dialysis dependent patients.
Risks/Contingencies: The $10 million payment and the ultimate assignment of the PRV are subject to the closing of the PRV Purchase by Vifor with a third party and satisfaction of customary closing conditions.
Investor Verification Checklist
- Confirm the closing status of the PRV Purchase between Vifor Pharma and the third party.
- Verify the terms of the definitive agreement for the assignment of the PRV to Akebia.
- Monitor the FDA review timeline for vadadustat to assess the impact of the PRV on approval speed.
- Review the impact of the $10 million contingent payment on Akebia's cash position upon closing.